In The News

Ropes & Gray Represents NeoGenomics in Collaboration with Inivata to Commercialize Lung Liquid Biopsy Test in U.S.

Practices: Life Sciences, Health Care, Health Care Finance & Restructuring, Health Care Transactions, Europe, Asset Management M&A, Technology, Media & Telecommunications, Digital Health

Ropes & Gray represented NeoGenomics Inc., a leader in liquid biopsy, in a strategic collaboration with Inivata for the commercialization of Cambridge, UK-headquartered Inivata’s InVisionFirst-Lung liquid biopsy test in the United States. The deal was announced on May 26. 

Under terms of the collaboration, NeoGenomics will make a $25 million equity investment in Inivata to take a minority shareholding with an option to buy the company outright. It will also take a seat on the Inivata Board of Directors. The new funding will be used by Inivata to further develop its innovative liquid biopsy technology and products. 

The Ropes & Gray team was led by health care partner Michael Lampert (Boston) and included private capital transactions partners John Newton and Alexander Robb (both of London), strategic transactions partners Thomas Fraser and Ed Kelly (both of Boston), tax partner Andrew Howard and private capital transactions associates David Dowling and Kenan Ceylan (all of London).

Cookie Settings